A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis
Public ClinicalTrials.gov record NCT02173301. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis
Study identification
- NCT ID
- NCT02173301
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Dr. Reddy's Laboratories Limited
- Industry
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- XP 23829 800 mg QD Drug
- XP23829 400 mg BID Drug
- XP23829 400 mg QD Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2014
- Primary completion
- Apr 30, 2015
- Completion
- Jul 31, 2015
- Last update posted
- Apr 11, 2022
2014 – 2015
United States locations
- U.S. sites
- 31
- U.S. states
- 19
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| XenoPort Investigational Site | Birmingham | Alabama | 35233 | — |
| XenoPort Investigational Site | Phoenix | Arizona | 85032 | — |
| XenoPort Investigational Site | Hot Springs | Arkansas | 71913 | — |
| XenoPort Investigational Site | Encinitas | California | 92024 | — |
| XenoPort Investigational Site | Fremont | California | 94538 | — |
| XenoPort Investigational Site | Fullerton | California | 92663 | — |
| XenoPort Investigational Site | Denver | Colorado | 80210 | — |
| XenoPort Investigational Site | Snellville | Georgia | 30078 | — |
| XenoPort Investigational Site | Buffalo Grove | Illinois | 60089 | — |
| XenoPort Investigational Site | Carmel | Indiana | 46032 | — |
| XenoPort Investigational Site | South Bend | Indiana | 46617 | — |
| XenoPort Investigational Site | Overland Park | Kansas | 66215 | — |
| XenoPort Investigational Site | Louisville | Kentucky | 40217 | — |
| XenoPort Investigational Site | Owensboro | Kentucky | 42303 | — |
| XenoPort Investigational Site | Boston | Massachusetts | 02111 | — |
| XenoPort Investigational Site | Watertown | Massachusetts | 02472 | — |
| XenoPort Investigational Site | Troy | Michigan | 48084 | — |
| XenoPort Investigational Site | Warren | Michigan | 48088 | — |
| XenoPort Investigational Site | Omaha | Nebraska | 68114 | — |
| XenoPort Investigational Site | East Windsor | New Jersey | 08520 | — |
| XenoPort Investigational Site | Verona | New Jersey | 07044 | — |
| XenoPort Investigational Site | Rochester | New York | 14623 | — |
| XenoPort Investigational Site | Stony Brook | New York | 11790 | — |
| XenoPort Investigational Site | High Point | North Carolina | 27262 | — |
| XenoPort Investigational Site | Goodlettsville | Tennessee | 37072 | — |
| XenoPort Investigational Site | Dallas | Texas | 75230 | — |
| XenoPort Investigational Site | Dallas | Texas | 75231 | — |
| XenoPort Investigational Site | Dallas | Texas | 75246 | — |
| XenoPort Investigational Site | San Antonio | Texas | 78218 | — |
| XenoPort Investigational Site | San Antonio | Texas | 78229 | — |
| XenoPort Investigational Site | West Jordan | Utah | 84088 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02173301, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 11, 2022 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02173301 live on ClinicalTrials.gov.